You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: L2 DIAGNOSTICS LLC Topic: NIAID
ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United StatesEurope and AsiaA member of the relapsing fever group of Borreliathis pathogen has been proven to cause most commonly a nonspecificflu like illness with feverfatiguemyalgiaand headacheDisease can be particularly severe and involve the central nervous system in immunocomprom ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: Elimu Informatics, Inc. Topic: 172
PROJECT SUMMARY Treatment with convalescent plasma (CP) was recently approved by the FDA for seriously ill patients of COVID-19. There are many institutions and hospitals that have implemented CP programs, but they all face the challenge of finding sufficient and appropriate donors. The constraints of matching, imbalances in supply and demand, and privacy concerns pose several challenges to engage ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: VLP BIOTECH, INC. Topic: NIAID
DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ALTRAVAX, INC Topic: NIAID
DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: WinSanTor, Inc. Topic: 101
PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: GENVEC, INC. Topic: 100
Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: Epigen Biosciences, Inc. Topic: 101
SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: Biospyder Technologies, Inc. Topic: 172
SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
A Unified System for Wireless Optogenetics and Brain Microdialysis for Small Molecules Prototype Development and ValidationSBC: AMUZA, INC Topic: 101
PROJECT SUMMARY While optogenetics is well suited for understanding the dynamic activity of neural circuits the first central theme of the NIH BRAIN Initiative PAR its neurochemical impacts remain largely uncharacterized due to a lack of appropriate tools Given that the predominant mode of cellular interactions is neurochemical commercial development of such tools will fulfill the ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: TRANSLATIONAL SCIENCES INC Topic: NHLBI
Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reducing disability and it is associated with brain hemorrhage in up toof patients when serial imaging studies are performedBrain hemorrhage causes death and disability andis the major cause of early morta ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health